This company develops small molecule therapeutics targeting inflammatory and metabolic diseases by addressing barrier dysfunction. Their drug design platform aims to restore healthy gut barriers, potentially improving outcomes for patients with inflammatory, autoimmune, and neuronal disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Many inflammatory, autoimmune, metabolic, and neuronal disorders exhibit gut barrier dysfunction, characterized by a compromised intestinal lining. This dysfunction allows microbes and antigens to translocate into systemic circulation, triggering hyperinflammation and organ-specific immune responses. Current therapies primarily target inflammation without directly addressing the underlying barrier defect.
Solution
Artus Therapeutics is developing first-in-class oral small molecule therapeutics designed to enhance the integrity of both epithelial and endothelial cell barriers in the gut. Inspired by naturally occurring host and microbial metabolites, these new molecular entities (NMEs) aim to restore a healthy gut barrier and prevent the leakage of intestinal contents into the bloodstream. Unlike existing treatments, Artus's lead candidates, including Artx-405, Artx-413, and Artx-425, facilitate mucosal healing without compromising immunity. The Artx platform has the potential to treat a range of gastrointestinal, neurological, and metabolic disorders by directly targeting and repairing barrier dysfunction.
Target Audience
The primary target audience includes patients suffering from inflammatory, autoimmune, metabolic, and neuronal disorders associated with gut barrier dysfunction, as well as clinicians seeking novel therapeutic approaches.
Features
- Orally administered small molecule therapeutics for convenient delivery
- Designed to enhance both epithelial and endothelial barrier integrity
- Inspired by naturally occurring host and microbial metabolites
- Lead candidates: Artx-405, Artx-413 and Artx-425
- Facilitates mucosal healing without compromising immunity